Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Drug:
belinostat
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CTRG-HC06/21/05
, NCI-7237, 7237, NCT00321594
2.
Trial of PXD101 in Combination With Idarubicin to Treat Acute Myeloid Leukemia (AML) Not Suitable for Standard Intensive Therapy
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PXD101-CLN-15
, NCT00878722
3.
Study of PXD101 and Doxorubicin to Treat Soft Tissue Sarcomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PXD101-CLN-14
, NCT00878800
4.
Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PXD101-CLN-6
, NCT00274651
5.
Phase II Study of PXD101 in Patients With Myelodysplastic Syndromes
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0581
, 7258, NCI-7258, NCT00357162
6.
Phase II Study of Belinostat in Patients With Recurrent or Metastatic, Unresectable Thymoma or Thymic Carcinoma Previously Treated With Prior Platinum-Containing Chemotherapy
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0033
, 08-C-0033, 8174, NCT00589290, NCI-P07249
7.
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PXD101-CLN-19
, NCT00865969
8.
Phase I Study of PXD101 and Bortezomib in Patients With Advanced Solid Tumors or Lymphomas
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
UCHSC-05-0705
, COMIRB 05-07-05, 7281, NCI-7281, UCHSC-COMIRB-05-0705, NCT00348985
9.
Phase I Study of PXD101 and Isotretinoin in Patients With Metastatic or Unresectable Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CCC-PHI-53
, 7251, NCI-7251, NCT00334789
10.
Phase I Partially Randomized Study of PXD101 and Azacitidine in Patients With Advanced Hematologic Cancers or Other Diseases
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-14510A
, 14510A, 7285, NCI-7285, NCT00351975
11.
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PXD101-CLN-9
, NCT00413075
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute